Hims & Hers Health, Inc. (NYSE:HIMS) Insider Michael Chi Sells 17,303 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 17,303 shares of the business’s stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $27.97, for a total value of $483,964.91. Following the sale, the insider now directly owns 193,601 shares of the company’s stock, valued at $5,415,019.97. This represents a 8.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Michael Chi also recently made the following trade(s):

• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $26.00, for a total value of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.
• On Friday, October 25th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.00, for a total value of $380,688.00.
• On Monday, October 21st, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.20, for a total value of $166,500.00.

Hims & Hers Health Stock Performance

HIMS stock opened at $26.56 on Friday. The company has a market capitalization of $5.80 billion, a price-to-earnings ratio of 60.37 and a beta of 1.25. Hims & Hers Health, Inc. has a fifty-two week low of $8.09 and a fifty-two week high of $35.02. The stock has a fifty day moving average of $26.37 and a 200-day moving average of $21.49.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter last year, the company earned ($0.04) EPS. The firm’s revenue was up 77.1% compared to the same quarter last year. Equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on HIMS. TD Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their price target for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Canaccord Genuity Group raised their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Finally, Morgan Stanley assumed coverage on Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $22.80.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. boosted its stake in Hims & Hers Health by 102.0% in the 3rd quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock worth $5,349,000 after purchasing an additional 146,621 shares during the period. Sanctuary Advisors LLC boosted its stake in Hims & Hers Health by 26.8% in the 3rd quarter. Sanctuary Advisors LLC now owns 26,057 shares of the company’s stock worth $480,000 after purchasing an additional 5,505 shares during the period. Neo Ivy Capital Management bought a new stake in shares of Hims & Hers Health during the 3rd quarter valued at about $1,252,000. Geode Capital Management LLC boosted its position in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after acquiring an additional 482,177 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Hims & Hers Health by 9.7% during the 3rd quarter. Barclays PLC now owns 308,363 shares of the company’s stock valued at $5,680,000 after acquiring an additional 27,231 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.